Titan Medical (NASDAQ:TMDIF) vs. SI-BONE (NASDAQ:SIBN) Head-To-Head Review

SI-BONE (NASDAQ:SIBN) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.

Profitability

This table compares SI-BONE and Titan Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SI-BONE	-31.20%	-28.22%	-20.53%
Titan Medical	N/A	-105.57%	-21.00%

Insider & Institutional Ownership

98.1% of SI-BONE shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 5.4% of SI-BONE shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares SI-BONE and Titan Medical’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$138.89 million	4.84	-$43.34 million	($1.14)	-14.36
Titan Medical	$20.09 million	0.29	-$42.54 million	($0.04)	-1.29

Titan Medical has lower revenue, but higher earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

SI-BONE has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Titan Medical has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for SI-BONE and Titan Medical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0	0	5	0	3.00
Titan Medical	0	0	0	0	N/A

SI-BONE currently has a consensus price target of $26.33, indicating a potential upside of 60.86%. Given SI-BONE’s higher possible upside, research analysts plainly believe SI-BONE is more favorable than Titan Medical.

Summary

SI-BONE beats Titan Medical on 8 of the 13 factors compared between the two stocks.

About SI-BONE

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Titan Medical

Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.